These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11106695)

  • 21. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.
    Kirsh V; Kreiger N
    Cancer Causes Control; 2002 Aug; 13(6):583-90. PubMed ID: 12195648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen-progestin replacement therapy: regulatory action needed.
    Pike MC; Ross RK
    Breast Cancer Res; 2002; 4(6):222-3. PubMed ID: 12473167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer and hormone replacement therapy: putting the risk into perspective.
    Campagnoli C; Abbà C; Ambroggio S; Biglia N; Ponzone R
    Gynecol Endocrinol; 2001 Dec; 15 Suppl 6():53-60. PubMed ID: 12227887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical?
    Shapiro S
    Climacteric; 2015 Jun; 18(3):333-5. PubMed ID: 25651904
    [No Abstract]   [Full Text] [Related]  

  • 27. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
    Kerlikowske K; Cook AJ; Buist DS; Cummings SR; Vachon C; Vacek P; Miglioretti DL
    J Clin Oncol; 2010 Aug; 28(24):3830-7. PubMed ID: 20644098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. So far, victories are few as breast cancer patients sue Wyeth over hormone therapy.
    Twombly R
    J Natl Cancer Inst; 2007 Dec; 99(24):1828-9, 1835. PubMed ID: 18073368
    [No Abstract]   [Full Text] [Related]  

  • 29. Postmenopausal estrogens--opposed, unopposed, or none of the above.
    Willett WC; Colditz G; Stampfer M
    JAMA; 2000 Jan; 283(4):534-5. PubMed ID: 10659883
    [No Abstract]   [Full Text] [Related]  

  • 30. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oestrogens and progestins and breast cancer risk in post-menopausal women.
    La Vecchia C
    Pharmacol Res; 1995 Dec; 32(6):323-4. PubMed ID: 8736479
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of oestrogens and progestin and the risk of breast cancer in post-menopausal women. G.A. Colditz et al. N. Engl. J. Med. 1995; 332: 1589-93.
    Kauppila A
    Pharmacol Res; 1995 Dec; 32(6):327. PubMed ID: 8736481
    [No Abstract]   [Full Text] [Related]  

  • 33. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.
    Colditz GA
    Breast Cancer Res; 2007; 9(4):108. PubMed ID: 17666116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does post-menopausal hormone-replacement therapy increase risk for breast cancer? A perspective on the findings of the Nurses' Health Study.
    Herd JA; Gotto AM
    Pharmacol Res; 1995 Dec; 32(6):331-3. PubMed ID: 8736483
    [No Abstract]   [Full Text] [Related]  

  • 38. The breast and the menopause.
    Wren BG
    Baillieres Clin Obstet Gynaecol; 1996 Sep; 10(3):433-47. PubMed ID: 8931904
    [No Abstract]   [Full Text] [Related]  

  • 39. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution.
    Chlebowski RT; Prentice RL
    J Natl Cancer Inst; 2008 Oct; 100(19):1341-3. PubMed ID: 18812547
    [No Abstract]   [Full Text] [Related]  

  • 40. Estrogen plus progestin, benefits and risks: the "Women's Health Initiative" trials.
    Keller KB; Lemberg L
    Am J Crit Care; 2005 Mar; 14(2):157-60. PubMed ID: 15728959
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.